TH64346A - Pharmacodynamic constituents in the treatment of tissue damage Due to failure of the blood circulation of the aorta - Google Patents

Abstract

This invention is about human medicine. And, in particular, containing pharmaceutical compounds that are made with Epidermal Growth Factor (EGF) and hexapeptide that stimulates Secretion of growth hormone secretagoge hexapeptide (GHRP); In defensive use Tissue damage Due to pressing the blood circulation And in enhancing tissue repair After the damage from the lack of blood Aggregate above May be used in elemental forms On the other hand, people may receive both EGF and GHRP separately, but in A single therapeutic scheme for increasing cell survival When the organs lose blood circulation Is a critical period This compound reduces the formation of reactive oxygen species (ROS) and its associated cytotoxicity. This compound is useful in enhancing Cell survival on tissues The compound may be used as a protective agent in people prone to multiple organ failure (MOF), such as those with burns, those with Sick with multiple wounds, newborns with hypoxia, acute respiratory disease. And patients with small intestine And colitis, which causes tissue or cells to die.This invention involves human medicine And, in particular, with pharmacological inclusions made with Epidermal Growth Factor (EGF) and Hexapeptide that stimulates screening Secretion of angry hormone (Growth Horrnone Sccrctagogehoxapertide) (GHRP) to prevent Tissue damage Due to pressing the blood circulation And in enhancing tissue repair after damage from blood shortage The above combination May be used as a pharmaceutical mixture Single science On the other hand, one may be exposed to both EGE and GHRP separately, but in a different way. Single therapy to increase cell survival When the organs lose blood circulation for a period of time One crisis This mixture reduces the formation of reactive oxygen species (ROS) and its associated cytotoxicity. This mixture is useful in enhancing the survival of Cells upon tissue Or organs exposed to prolonged periods of blood shortages. The mixture may be used in Protective agent form in people prone to multiple organ failure (MOF) such as burns, multiple wounds, hypoxia newborn children, pathologies. Acute breathing And patients with small intestine And colitis, which causes tissue or cells to die.

Claims (9)

1. Pharmacy mixtures Which is characterized by providing a peptide Which has the agility of Epidemnal Growth Factor in combination with hexapeptide That stimulate secretion Of growth hormoneseeretagotue hexapeptide (GHRP-6) for preventing and treating tissue damage This is due to lack of arterial blood flow and its consequences in animals and humans. 2. Pharmacodynamic mixtures according to claim 1, in which the epidider-active peptide Mol Rage Factor can be Epidermal Rage Factor (EGF), Transforming Growth Factor type alpha (TGF-Alpha) or Rage Factor. Heparin Binding EGF (Heparin Binding EGF-Like Growth Factor) (HB-EGF) 3. Pharmacy mixtures according to Clause 1, which the peptide with Epide agility. A Mol Rage Factor and Hexapeptide that stimulates the secretion of raging hormone GHRP-6 is a component of a single pharmacological compound with an additional appropriate exponent. Pharmacy according to claim 1, which provides a secretory-stimulating hexapeptide. Of the angry hormone GHRP-6 alone or in combination with the epidite-agile peptide Mol angered the independent factor to the patient. As part of prevention or treatment 5. One of the Pharmacy Mixture according to Clause 1 to 4. Which the peptide has Epidermal rage factor is at a concentration of 0.5-50 μg / ml. When prepared in either solvent form or in iophilisation form 6. Pharmacy mixtures according to Clause 1 to 4, which Hexapeptide that Stimulate the secretion of the angry hormone GHRP-6 at a concentration of 2 y 100 μg / ml. When prepared in solution Or in the form of lyophilis. 7. Pharmacological compound according to Clause 1 to 6, any one Which must be given without passing A single dose of large intestine (bolnus) to provide defensive agility. Induced in a dose range of 0.5-1 μg of each active peptide per kilogram of body weight. 8. Pharmacodynamic mixtures according to Claim 1 to 6. Which must be provided in the form Sustained intravenous infusion for induction of transformation / regeneration in the 0.01 y 5 μg dose range of each active peptide per kg of patient body weight. 9. Pharmacodynamic mixtures. Which is characterized by the presence of hexapeptide that stimulates selective The secretion of the angry hormone GHRP-6 and the appropriate expectorant to induce protection against Damaged by lack of blood In order to prevent tissue damage When there is blood circulation Of the aorta fluids in humans and animals 1 0. Use of one of the pharmacological mixtures of claims 1 to 8 for the prevention of serious or serious tissue damage. Or not in the affected tissue / or organ Affected by non-circulatory insufficiency, poor circulation, or lack of blood / rehydration 1 1. The use of a pharmacokinetic mixture pursuant to one of Clause 1 to 8 of claim 1 to 8 for mitigation or correction of adjuvant treatment of adult respiratory distress (ARDS) 1. 2. The use of one of the Pharmacy Mixture according to Clause 1 to 8 for the prevention and correction of multiple organ dysfuncthin syndrome and related processes required for treatment. Strict supervision 1 3. The use of pharmaceutical mixtures according to claim 12 for the treatment of burned wounds, multiple trauma patients, wide area surgical patients, surgical patients. Implants, patients who have surgery with new tubes or tubes, patients who have been connected to Heart-Lung apparatus, Patients receiving thrombolytic and / or fibrinolysis treatment and recirculation, Crush syndromes, ischemic patients, shock , The productivity of the heart is low 1 4. Use of any one of Clause 1 to 8 of the Pharmacy Mixture to Adjuvant treatment for bleeding, abnormal fluid distribution, shock and deficiency. Blood / visceral passage of new fluids 1 5. Use of any Pharmacy Mixture according to Claim 1 to 8 as a Preventive Agent and a Pre-Used Substance for Transplant Surgery, Prolonged Blood Shortage Caused by Surgery. And one other condition that causes the early stages of blood shortage. Of internal organs Disease responsive to systemic inflammation And malfunctions of many organs 1 6. Use of the pharmaceutical mixture according to claim 15 to maintain the equilibrium of Internal environment of organs And internal membranes during surgery to have new tubes or tubes and to enhance the survival of any implants after transplantation such as kidneys, liver, pancreas, intestines, lungs, heart and skin plates 1 7. Use of any one of Clause 1 to 8 of the Pharmacy Mixture in the Prevention of Cell Damage. After any conditions which can impede the passage of membrane fluids with oxygenated blood 1 8. Use of any Pharmacy Mixture according to Clause 1 to 8. In acting Coordination through the functional patterns of tissues / organs After a case in which the results after that lead to death Of tissue Or group of cells 1 9. Use of any Pharmacy Mixture in accordance with Clause 1 to 8 for stimulation. Bowel adaptation processes After removal of part of the intestine, short bowel disease, bowel failure, etc., related or not related to total parpenteran nutrition.